Metabolomics and biomarker discovery represent the leading edge of contemporary biomedical research, providing powerful inferences regarding the complex biochemical processes before and during states of health, disease and intervention. Metabolomics is defined by the investigation of small-molecule metabolites in biological systems and inherently repertoires a snapshot of the physiological changes that occur throughout each of the stimuli, interventions or diseases in question. Advances in high-throughput platforms include expanded reliance on mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy and even hyperpolarized MRI approaches to identify potential biomarkers for early diagnosis, prognosis, and ongoing monitoring of treat-throughout acute and chronic disease processes. The investigation of metabolomics with genomic, proteomic and transcriptomic datasets effectively operates within the established paradigm of systems biology, which is explorative in precision medicine and personalized treatment. This session will explore some of the latest advances and methods in metabolite profiling and biomarker validation across different disease models.
Connect, collaborate, and contribute to driving excellence in obesity research, clinical practice, and public health approaches globally.
